Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 14/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.34 |
| ▸ | MERTK | Q12866 | 1/20 | 0.34 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.34 |
| ▸ | NMBR | P28336 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4682888 | 0.99 | SIRT2 (0.46) | SIRT2CYP11B1CYP11B2ENPP2FLT3 | |
| SCHEMBL2032778 | 0.94 | SIRT2 (0.47) | SIRT2CYP11B1CYP11B2ENPP2NMBR | |
| Lithium Ion SCHEMBL18991219 | 0.90 | SIRT2 (0.45) | SIRT2CYP11B1CYP11B2ENPP2NMBR | |
| SCHEMBL1041048 | 0.88 | SIRT2 (0.49) | SIRT2CYP11B1CYP11B2ENPP2FLT3 | |
| SCHEMBL8165853 | 0.85 | SIRT2 (0.47) | SIRT2CYP11B1CYP11B2ENPP2TBXAS1 | |
| SCHEMBL25310574 | 0.85 | MAPT (0.45) | SIRT2TBXAS1 | |
| SCHEMBL25389258 | 0.85 | MAPT (0.45) | SIRT2TBXAS1 | |
| SCHEMBL25389429 | 0.85 | MAPT (0.45) | SIRT2TBXAS1 | |
| SCHEMBL25390529 | 0.85 | MAPT (0.45) | SIRT2TBXAS1 | |
| SCHEMBL6959210 | 0.84 | SIRT2 (0.46) | SIRT2CYP11B1CYP11B2ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6355665-B1 | ANTIHISTAMINES, ANTIALLERGENS AND IRRITABLE BOWEL SYNDROME. | JAMES BLACK FOUNDATION LIMITED (GB) | 2002-03-12 | — | — | US | disclosed |